Trustees' Annual Report for the period

From 1st January 2025 To 31st December 2025

Charity name: Salivary Gland Cancer UK

Charity registration number: 1182762

Objectives and Activities

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	Help those affected by rare salivary gland cancers. Advocate for these patients and carers by providing peer support and information about their disease, care and treatment. Promote and assist research into all aspects of salivary gland cancers, including causes, diagnosis, treatments and cures. To educate the public and healthcare communities in all things related to salivary gland cancers, including raising awareness of symptoms.
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.	Para 1.17 and 1.19	• Supporting the community via in person and virtual meetings for patients, carers and clinicians. • Providing information and increasing awareness via leaflets, meetings, the website, social media and fundraising events. • Raising awareness of these cancers and their unmet need via speaking, submitting materials and attending meetings and conferences. • Expansion of the network to support all salivary gland cancer types. • Expansion of the charity's outputs to provide more research and disease specific information.
Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit	Para 1.18	The trustees have kept in mind the charity Constitution and the guidance from the Charities Commission in all of its' activities. The governance documents of the Charity are regularly reviewed at Trustee meetings.

		The charity's "8 aims" are regularly published via our social media outlets and are the foundation for all activities and decisions within the charity. The trustees ensure the prioritisation of activities is aligned with these aims.

Additional information (optional)

You may choose to include further statements where relevant about:

	SORP reference	
Policy on grant making	Para 1.38	We invest directly in research infrastructure. Our first grant call funded projects mapping the pathway to diagnosis and developing guidance to support earlier detection. We have supported the rollout of a UK-wide surgical registry, which collects clinical and patient-reported outcomes data to improve understanding of treatment outcomes and disease progression. We also rolled out our very first travel grant so our community can apply for financial support to travel to a relevant conference or workshop that is aligned with our strategy as a charity. This is available to those who do not otherwise receive funding to attend such events e.g. medical undergraduates, allied healthcare professionals and patient advocates.
Policy on social investment including program related investment	Para 1.38	
Contribution made by volunteers	Para 1.38	We are hugely grateful for the continued support and contribution we received from our volunteers assisting us in specific projects and outputs, sharing their stories on social media channels, and 'on the day' physical support at both our own events and conferences we attend.
Other		

Achievements and Performance

	SORP reference	
Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	***Launch of annual Salivary Gland Cancer Day – 4th October 2025*** SGC Day was launched on 4 October 2025 at Manchester Art Gallery - the first awareness day dedicated to these cancers in the UK. The initiative was created to address a major barrier to progress: the lack of public and professional awareness surrounding salivary gland cancers. Through coordinated social media campaigns, patient storytelling and community engagement, the day brought unprecedented visibility to SGCUK and these rare diseases. Patients, clinicians and supporters across the UK and internationally participated. Social media posts were created in 25 languages ensuring as wide a reach as possible. The success of the inaugural annual awareness day has established a powerful platform for future national awareness campaigns. ***Bringing together those living with salivary gland cancers*** We continued to host bi-annual hybrid (in person/virtual) meetings during 2025, supporting attendees with travel bursaries for patients and their carers where needed. The hybrid structure of our events has facilitated strong attendance from our community across the country and internationally. In May 2025 we hosted a gathering in Sheffield and October 2025's event was in Manchester. We provided regular communications, newsletters and updates to the network. We continued to produce our video series, releasing recordings of the presentations at our hybrid meetings to ensure we reach as many people as possible. We also continued to add patient stories on social media and on our website. We also hosted a number of 'stop by' sessions online where the community could

		drop in for a chat with members of our team about anything they wanted to discuss. ***Raising awareness amongst the general public and the clinical community*** We continue to work to increase our visibility among the clinical and patient network by attending and presenting at various conferences and events. In March we attended ESMO Rare Cancers Congress where Dr Metcalf delivered a presentation on behalf of the UK Salivary Gland Cancer Research Working Group (UKSGCRWG), titled “Advancing Salivary Gland Cancer Research: A Multidisciplinary Approach to Addressing the Unmet Clinical Need.” In June, we chaired a panel discussion at the inaugural National Patient Data Day, hosted by use MY data, delving into the critical question: 'Can we create a UK-wide data environment fit for international rare disease research?' In July we attended IAOO2025, where we had a stall and our CEO Dr Emma Kinloch delivered a keynote speech on patient voices in research. IAOO 2025 is the 10th World Congress of the International Academy of Oral Oncology, bringing together over 1,000 delegates from various disciplines involved in oral cancer care. We attended the Swallows Head and Neck Conference in November to ensure SGC patient needs are represented in discussions on the latest surgical and radiotherapy treatments. We also joined the Cancer Drug Development Forum (CDDF) workshop in November, titled "Enabling Smarter Clinical Trials to Optimise Patient Care." Our Patient and Public Involvement (PPI) work has continued to grow and develop in 2025. We are regularly called upon to input into the design of research studies, provide feedback on trial protocols, help researchers develop lay summaries of their work and bring the perspective of those with lived experiences to discussions.

		Many fundraising events, both large and small, have taken place during the year, notably our supporters' participation in the London and Loch Ness Marathons and The Big Half in London. ***Bringing together the patient, clinical and research communities to help drive forward research and improvements in treatments*** Our Research Working Group has been very active during 2025. Consisting of clinicians, researchers and patient advocates from all around the UK and beyond. The group meets twice a year in full with 4 separate workstreams meeting throughout the year to focus on their individual topics in line with the charity's aims. Our involvement on the PRONTO trial management committee continued as it opened for recruitment at The Christie and UCLH, representing a significant step forward in optimising care for Salivary Gland Cancer. The primary focus of this study is on patient quality of life.

Additional information (optional)
You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	
Performance of fundraising activities against objectives set	Para 1.41	
Investment performance against objectives	Para 1.41	
Other		

Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	As at 31st December 2025 the charity held a cash balance of £50,077, (prior year £68,381). The charity had an in-year deficit of £18,304 (prior year deficit £36,451). The charity received income of £39,609 (prior year £37,336) from donations raised through fund raising initiatives and personal legacies. The charity's accounts for the year have been independently reviewed with no issues raised. Despite an in-year deficit, the charity's financial position remains robust. There are substantial fundraising activities planned for 2026 and we are predicting an in-year surplus.
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	The cash balance is held in order to support the overall objectives of the charity. Cash is used to cover operating expenses, develop the charity's presence through marketing and fund specific patient/clinician events. Cash held is also the source funds for the grants we have issued and for any other grant making opportunities that may arise.
Amount of reserves held	Para 1.22	£50,077 in cash.
Reasons for holding zero reserves	Para 1.22	Not applicable
Details of fund materially in deficit	Para 1.24	Not applicable
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	There are no uncertainties around the charity's ability to continue as a going concern. The Board, together with the CEO, carefully consider the on-going running costs of the charity when assessing the funds available for grants and other events.

Additional information (optional)

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	
Investment policy and objectives including any social investment policy adopted	Para 1.46	
A description of the principal risks facing the charity	Para 1.46	The Board maintains a Risk Register for the charity. This document highlights governance, operational, financial, compliance and external risks and the mitigants in place. The Board reviews the Risk Register periodically.
Other		

Structure, Governance and Management

Description of charity's trusts:		
Type of governing document (trust deed, royal charter)	Para 1.25	The charity is governed by its Constitution.
How is the charity constituted? (e.g unincorporated association, CIO)	Para 1.25	The charity is a Charitable Incorporated Organisation.
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	Trustees must be appointed for a term by a resolution passed at a properly convened meeting of the charity trustees. When selecting trustees, the charity trustees have regard to the skills, knowledge and experience needed for the effective administration of the CIO. The Board periodically reviews a detailed skills matrix to identify any gaps and regularly discusses the structure and composition of the Board to ensure its ongoing effectiveness as a governing body.

Additional information (optional)
You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction and training of trustees	Para 1.51	All new trustees undertake an induction process which includes receiving an induction pack containing relevant policies, procedures and key organisational information, together with an individual meeting with the CEO. Prospective trustees are also invited to attend Board meetings as observers prior to their formal appointment, enabling them to gain an understanding of the charity's governance, operations and responsibilities of trustees. Ongoing training and development needs are identified as appropriate throughout their tenure.
The charity's organisational structure and any wider network with which the charity works	Para 1.51	
Relationship with any related parties	Para 1.51	
Other		

Reference and Administrative details

Charity name	Salivary Gland Cancer UK
Other name the charity uses	
Registered charity number	1182762
Charity's principal address	International House 36-38 Cornhill City of London London EC3V 3NG

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1	Dr Robert Metcalf	Trustee		The Board
2	Shane Lisa Draper	Trustee and Chief Financial Officer		The Board
3	Olorunkemi Fausat Akanke Olaiya	Treasurer	**Non-Board role	The Board
4	Jacqueline O'Connor	Chair of Board	Start date – December 2025	The Board
5	Sally Crowe	Trustee	Start date – December 2025	The Board
6	Barry Thomas	Trustee	Start date – December 2025	The Board

Corporate trustees – names of the directors at the date the report was approved

Director name		

Name of trustees holding title to property belonging to the charity

Trustee name	Dates acted if not for whole year	

Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	Not applicable
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	Not applicable
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	Not applicable

Additional information (optional)

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address

Name of chief executive or names of senior staff members (Optional information)

Dr Emma Kinloch - CEO

Exemptions from disclosure

Reason for non-disclosure of key personnel details

Other optional information

Declarations

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)		
Full name(s)	Jacqueline O'Connor	Shane Lisa Draper
Position (eg Secretary, Chair, etc)	Chair of the Board of Trustees	Chief Financial Officer
Date	19.10.26	19.10.26

CHARITY COMMISSION FOR ENGLAND AND WALES

Salivary Gland Cancer UK	No (if any) 1182762

Receipts and payments accounts

CC16a

For the period from	Period start date 1st January 2025	To	Period end date 31st December 2025

Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
A1 Receipts					
Donations via Just Giving, Easy Fundraising, Paypal and other platforms	35,740	-	-	35,740	24,029
Donations received from organisations/individuals	2,197	-	-	2,197	11,183
Grants from organisations/collaboration agreements	-	-	-	-	840
Shop income	384	-	-	384	-
Other income	325	-	-	325	-
Bank interest	964	-	-	964	1,285
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total *(Gross income for AR)*	39,609	-	-	39,609	37,336
A2 Asset and investment sales, (see table).					
	-	-	-	-	
	-	-	-	-	-
Sub total	-	-	-	-	-
Total receipts	39,609	-	-	39,609	37,336
A3 Payments					
Charity admin expenses and running costs	37,807	-	-	37,807	33,073
In person meeting expenses e.g. room hire	17,112	-	-	17,112	17,379
Bursaries for attendees	124	-	-	124	508
Memberships and collaborative expenses	665	-	-	665	316
Entry into events for members fundraising	1,270	-	-	1,270	1,510
Grants	936	-	-	936	21,000
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total	57,913	-	-	57,913	73,787
A4 Asset and investment purchases, (see table)					
	-	-	-	-	
	-	-	-	-	
Sub total	-	-	-	-	-
Total payments	57,913	-	-	57,913	73,787
Net of receipts/(payments)	(18,304)	-	-	- 18,304	- 36,451
A5 Transfers between funds	-	-	-	-	-
A6 Cash funds last year end	68,381	-	-	68,381	104,832
Cash funds this year end	50,077	-	-	50,077	68,381

Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B1 Cash funds	Bank account balance (Lloyds)	16,268	-	-
	Notice account (Lloyds)	32,856	-	-

	Paypal account balance	953	-	-
	Total cash funds	**50,077**	**-**	**-**
	account(s))	OK	OK	OK
		Unrestricted funds	**Restricted funds**	**Endowment funds**
	Details	**to nearest £**	**to nearest £**	**to nearest £**
B2 Other monetary assets		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-

	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
B3 Investment assets			-	-
			-	-
			-	-
			-	-
			-	-

	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
B4 Assets retained for the charity's own use			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-

	Details	Fund to which liability relates	Amount due (optional)	When due (optional)
B5 Liabilities			-	
			-	
			-	
			-	
			-	

Signed by one or two trustees on behalf of all the trustees

Signature





Print Name

Jacqueline O'Connor

Shane Draper

Date of approval

19.10.26

19.10.26

CHARITY COMMISSION
FOR ENGLAND AND WALES

Independent examiner's report on the accounts

Report to the trustees/ members of	Charity Name Salivary Gland Cancer UK		
On accounts for the year ended	31st December 2025	**Charity no (if any)**	1182762
Set out on pages	1-2 (remember to include the page numbers of additional sheets)		

I report to the trustees on my examination of the accounts of the above charity ("the Trust") for the year ended **31st December 2025**.

Responsibilities and basis of report

As the charity trustees of the Trust, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention (other than that disclosed below *) in connection with the examination which gives me cause to believe that in, any material respect:

- accounting records were not kept in accordance with section 130 of the Act or
- the accounts do not accord with the accounting records

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in order to enable a proper understanding of the accounts to be reached.

* *Please delete the words in the brackets if they do not apply.*

Signed:	[signature]	**Date:**	30/9/26
Name:	Mrs Karen Wicks		
Relevant professional qualification(s) or body (if any):	Accountant		
Address:	On request		

Only complete if the examiner needs to highlight matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

Give here brief details of any items that the examiner wishes to disclose.

None